Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Johnson & Johnson vs. Pfizer


Better Buy: Johnson & Johnson vs. Pfizer

They're two of the oldest, largest, and most respected healthcare companies around. But one has made investors much happier than the other in recent years. Johnson & Johnson (NYSE: JNJ) stock is up more than twice as much as Pfizer (NYSE: PFE) stock over the past five years, and it's a similar story so far in 2017.

That's looking in the rearview mirror, though. Which of these healthcare stocks is the better choice for long-term investors now? Here's how Johnson & Johnson and Pfizer compare.

Image source:Getty Images.

Continue reading


Source: Fool.com

Johnson & Johnson Stock

€148.34
0.720%
The Johnson & Johnson stock is trending slightly upwards today, with an increase of €1.06 (0.720%) compared to yesterday's price.
With 40 Buy predictions and 1 Sell predictions Johnson & Johnson is one of the favorites of our community.
As a result the target price of 187 € shows a positive potential of 26.06% compared to the current price of 148.34 € for Johnson & Johnson.
Like: 0
JNJ
Share

Comments